Sankyo to Launch Osteoporosis Treatment Drug in Europe.
Raloxifene is a selective estrogen receptor modulator, specifically developed to maintain beneficial estrogenic activity on bone and lipids and antiestrogenic activity on endometrial and breast tissue.
It slows bone loss and slightly increases normal bone growth. Because of its tissue selectivity, raloxifene may have fewer side effects than are typically observed with estrogen therapy including vaginal bleeding and breast tenderness.
There still needs more proof that raloxifene can also prevent bone fractures or lowers the risk of heart disease.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Jul 19, 2006|
|Previous Article:||Trans Genic and Kumamoto Foundation Conclude Anti-HIV Antibody License Agreement.|
|Next Article:||Yano Research Institute Surveys on One-Seg.|